Indegene drove new-to-brand prescriptions for a global science-led biopharmaceutical company's existing Type II diabetes drug in whitespace areas of the GLP-1-RA market. Challenges included amplifying growth for the non-insulin injectable among an unsegmented universe of 150,000 potential HCPs, losing revenue potential from disengaged prescribers, and lacking infrastructure to optimize promotional campaigns. Indegene's software segmented HCPs precisely, built scalable campaign infrastructure, and powered targeted engagement, successfully generating 130,000 new-to-brand prescriptions and unlocking whitespace revenue growth.

Join for free to read